PMID: 8946624Nov 1, 1996Paper

Immunotherapy and gene therapy

Seminars in Urologic Oncology
B GitlitzR Figlin

Abstract

Currently, there are many options for the treatment of metastatic renal cell carcinoma (RCC). Being a mostly chemoresistant malignancy, renal cell carcinoma is usually treated with immunotherapy. These therapies are generally based on interleukin-2 (IL-2) or interferon alfa (IFN-alpha), or involve more novel techniques such as gene therapy. IL-2 is a biological agent that has been approved by the U.S. Food and Drug Administration and leads to durable remissions in a subset of patients with metastatic RCC. Patients presenting with a good performance status and without serious concomitant cardiac or pulmonary disorders should be considered for IL-2-based therapy as first-line treatment.

References

Oct 1, 1992·The British Journal of Surgery·A D HillD Bouchier-Hayes
Aug 1, 1992·Journal of Immunotherapy·E WeidmannP S Mitrou
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·D T CurielM Cotten
Dec 1, 1991·The Journal of Experimental Medicine·H HockT Blankenstein
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·C A MullenR M Blaese
Jan 1, 1990·Cancer Immunology, Immunotherapy : CII·G P HaasS A Rosenberg
Oct 1, 1990·The Journal of Experimental Medicine·B GansbacherE Gilboa
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·Y WatanabeT Sakata
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P L FelgnerM Danielsen
Jan 1, 1988·Seminars in Surgical Oncology·A D GeboersO Damsma
Apr 9, 1987·The New England Journal of Medicine·W H WestR K Oldham
Jun 1, 1987·Annals of Internal Medicine·A BelldegrunS A Rosenberg
Sep 1, 1986·AJR. American Journal of Roentgenology·D L Nguyen, J C Leonard
Feb 1, 1987·Cancer·G SarnaJ de Kernion
Sep 15, 1984·International Journal of Cancer. Journal International Du Cancer·G PizzaF Corrado

❮ Previous
Next ❯

Citations

Feb 9, 2000·Radiologic Clinics of North America·E J Small, D M Reese

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.